Evidence map›Paper›PMID 38169905›Full record

ArticleFrontiers in public health2023

SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022.

Angela Koech, Geoffrey Omuse, Alex G Mugo, Isaac G Mwaniki, Joseph M Mutunga, Moses W Mukhanya, Onesmus Wanje, Grace M Mwashigadi, Geoffrey G Katana, Rachel Craik and 5 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Angela Koech *Centre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Geoffrey Omuse *Department of Pathology, Aga Khan University, Nairobi, Kenya.
Alex G MugoCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Isaac G MwanikiCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Joseph M MutungaCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Moses W MukhanyaCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Onesmus WanjeCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Grace M MwashigadiCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
Geoffrey G KatanaKilifi County Department of Health and Sanitation Services, Kilifi, Kenya.
Rachel CraikDepartment of Women and Children's Health, Kings College London, London, United Kingdom.
Peter von DadelszenDepartment of Women and Children's Health, Kings College London, London, United Kingdom.
Kirsty Le DoareSt. George's University of London, London, United Kingdom.
Marleen TemmermanCentre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
periCOVID-Africa
PRECISE Network

Funding

UZIMA-DS: UtiliZing health Information for Meaningful Impact in East Africa through Data ScienceU54TW012089 · FIC · AGA KHAN UNIVERSITY (KENYA) · PI Amina Abubakar Ali, Akbar K Waljee · 2021 to 2026
$7.7M
FIC NIH HHS U54 TW012089Medical Research Council MC_UU_00027/5Medical Research Council MR/P027938/1
6 · The paper itself

Abstract

Background: Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya. Methods: We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG). Results: A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0-0.06] in March 2020 to a high of 89.4% [95% CI 83.36-93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% [95% CI 57.06-62.34] tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 37.4% [95% CI 34.83-40.04] tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence. Conclusion: Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data.

Indexed as

COVID-19Pregnant PeopleAntibodies, ViralCohort StudiesFemaleHumansImmunoglobulin GKenyaPregnancySARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralImmunoglobulin GantibodiesCOVID-19KenyapregnancySARS-CoV-2seroprevalence

Identifiers

PMID38169905
PMCPMC10760635

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.